Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd at NWR Healthcare Conference (Virtual) Transcript

Mar 22, 2023 / 02:00AM GMT
Release Date Price: $0.8566
Matt Wright
NWR Communications - Moderator

Hello, and welcome back to the NWR Virtual Healthcare Conference. My name is Matt Wright. Next up, we have Paradigm Biopharmaceuticals, which is listed on the ASX under the ticker PAR. And joining us on behalf of Paradigm today is CEO Paul Rennie.

(Conference Instructions) I'll now pass it over to Paul to give the presentation. Please go ahead.

Paul Rennie
Paradigm Biopharmaceuticals Limited - Founder, Chairman, & MD

Thank you very much, Matt, and thank you, everyone, for attending. I'm very pleased to be here and present the Paradigm story. I'm just back from a major international conference on osteoarthritis, called OARSI, where many big pharma companies presented their data in relation to research that's going on within the field of osteoarthritis. And I was very, very privileged to say that Paradigm got invited to talk at the clinical trials symposia, where other pharma companies, along with Paradigm, spoke about their clinical development progress thus far.

And one of the amazing things

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot